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SUMMARY
Natural killer (NK) cells are cytotoxic innate lymphoid cells (ILCs) that mediate antiviral and antitumor re-
sponses and require the transcriptional regulator Eomesodermin (Eomes) for early development. However,
the role of Eomes and its molecular program inmature NK cell biology is unclear. To address this, we develop
a tamoxifen-inducible, type-1-ILC-specific (Ncr1-targeted) cre mouse and combine this with Eomes-floxed
mice. Eomes deletion after normal NK cell ontogeny results in a rapid loss of NK cells (but not ILC1s), with
a particularly profound effect on penultimately mature stage III NK cells. Mechanisms responsible for stage
III reduction include increased apoptosis and impaired maturation from stage II precursors. Induced Eomes
deletion also decreases NK cell cytotoxicity and abrogates in vivo rejection of major histocompatibility com-
plex (MHC)-class-I-deficient cells. However, other NK cell functional responses, and stage IV NK cells, are
largely preserved. These data indicate that mature NK cells have distinct Eomes-dependent and -indepen-
dent stages.
INTRODUCTION
Natural killer (NK) cells are the founding members of a family of
innate lymphoid cells (ILCs) (Colonna, 2018) that also includes
helper ILC1s, ILC2s, and ILC3s (Cherrier et al., 2018). NK cells
protect against infection and mediate antitumor responses via
two primary effector functions: production of immunomodula-
tory cytokines and direct cytotoxicity (Caligiuri, 2008; Vivier
et al., 2008). NK cells recognize target cells based on the integra-
tion of signals from numerous germline DNA-encoded activating
and inhibitory receptors. In general, activating receptors recog-
nize cell stress ligands, while inhibitory receptors recognize ma-
jor histocompatibility complex (MHC) class I molecules (Lanier,
2005). In addition, NK cells constitutively express cytokine re-
ceptors that support their development and tune their function
by ligating activating or inhibitory signals in the surrounding envi-
ronment (Romee et al., 2014; Yang et al., 2010).
The developmental and transcription factor programs of NK
cells are distinct from those of helper ILCs. ILC development be-
gins in the bone marrow (BM) from the common lymphoid pro-
genitor (CLP), which gives rise to both the NK and helper ILC lin-
eages. Thereafter, most terminal NK cell maturation takes place
in peripheral tissues (Cherrier et al., 2018; Yu et al., 2013). TheNK
progenitor (NKP) differentiates through several NK cell matura-
tion stages classically characterized based on the presence or
absence of the surface markers CD27 and CD11b (Chiossone
et al., 2009). In addition, the activating receptor NKp46, encoded
by Ncr1, is induced during stage I (CD27CD11b) of differenti-
ation, followed by the integrin CD49b (DX5), and MHC-class-I-
recognizing Ly49 activating and inhibitory receptors (Yu et al.,
2013). Numerous transcription factors are required to regulate
ILC development and promote the different lineages (Ishizuka
et al., 2016; Leong et al., 2017). NK cells and ILC1s both express
T-bet, but of type-1 ILCs, only NK cells express Eomesodermin
(Eomes), another T-box transcription factor critical for their
development (Colonna, 2018). Recent data have revealed that
NK cells and ILC1s exhibit plasticity depending on their environ-
ment and specifically that NK cells can convert to ILC1-like cells
in transforming growth factor b (TGF-b)-rich tumors and tissues
(Berrien-Elliott et al., 2019; Cortez et al., 2017; Gao et al.,
2017), which can involve downregulation of Eomes.
However, the mechanisms whereby modulation of Eomes
could alter NK cellular identity and function is unclear. Eomes,
like T-bet, regulates gene expression by binding T-box DNA ele-
ments. Eomes is generally required for early embryonic develop-
ment, as evidenced bymice with global Eomes gene deletion ex-
hibiting embryonic lethality (Russ et al., 2000). An important role
for Eomes has been demonstrated in CD8 T cell biology; it pro-
motes the development of central memory CD8 T cells as well
as the cytotoxic T cell effector program by positively regulating
interferon g (IFN-g), perforin, and granzyme B (Banerjee et al.,
2010; Intlekofer et al., 2005; Pearce et al., 2003). Eomes is also
critical for NK cell development, and mice with hematopoietic-
or constitutive NK-cell-specific Eomes deletion display a severe
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Figure 1. Tamoxifen Induces Robust and Type-1-ILC-Specific cre Activity in Mice Harboring the Ncr1-iCreERT2 Knockin Locus
(A) Schematic depicting the Ncr1-iCreERT2 locus and mouse model.
(B) Mean ± SEM type 1 ILC (NK1.1+CD3-) and T cell (CD3+) percent YFP+ in the blood (Bl), spleen (Sp), bonemarrow (BM), lymph node (LN), and liver (Liv) ofNcr1-
iCreERT2 3 Rosa26YFPLSL mice 2 days following three consecutive daily doses of 3 mg tamoxifen in corn oil (or no tamoxifen [No Tam]). Representative flow
cytometry data from the spleen of a tamoxifen-treated mouse shown to the right. n = 2–3 mice per group, two independent experiments.
(legend continued on next page)
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and global decrease in conventional NK cell numbers but pre-
served ILC1s (Daussy et al., 2014; Gordon et al., 2012; Pikov-
skaya et al., 2016). Eomes is expressed by NK cells of all matu-
ration stages, with highest expression in the relatively immature
stage II and III populations (Gordon et al., 2012). NK cell terminal
maturation is thought to rely on T-bet, whose expression in-
creases in terminally mature (stage IV) NK cells, opposite to
the decrease in Eomes (Daussy et al., 2014; Townsend et al.,
2004). Functionally, Eomes expression correlates with NK cell
IFN-g production in vivo (Gill et al., 2012) and Prf1 transcription
(Pearce et al., 2003), but T-bet has also been shown to regulate
NK cell cytotoxic protein expression (Townsend et al., 2004).
Thus, the importance of Eomes in mature NK cell homeostasis
and function remains unclear.
Studies of Eomes in NK cell homeostasis and function have
been limited by a lack of appropriate inducible genetic models.
In the constitutive Ncr1-cre models available (and similarly for
Vav1-cre), cre-driven Eomes deletion in immature BM NK cells
results in abrogation of NK cell development and thus precludes
the study of Eomes in mature NK cell biology (Gordon et al.,
2012; Pikovskaya et al., 2016). Indeed, what were once thought
to be Eomes-negative NK cells in such constitutive models are
now better understood to have been type 1 ILCs (Gordon
et al., 2012). To overcome this limitation, we developed a type-
1-ILC-specific tamoxifen-inducible cre mouse model and
confirmed its properties using a Rosa26-YFP reporter allele.
Eomes-floxed mice were crossed to this model in order to eluci-
date the role of Eomes in mature NK cell biology. Here, we
studied the impact of induced Eomes deletion on mature NK
cell homeostasis and function. We demonstrate that there are
Eomes-dependent (stage II/III) and independent (stage IV) mu-
rine NK cell subsets and that loss of Eomes does not reverse
NK cell maturation, as has been previously suggested (Gordon
et al., 2012). In addition, we demonstrate a requirement of
ongoing Eomes expression for NK cell cytotoxicity and in vivo re-
sponses to MHC-I-deficient target cells.
RESULTS
The Ncr1-iCreERT2 Tamoxifen-Inducible cre Model
Specifically Activates cre within Type 1 ILCs
Mouse models with constitutive type 1 ILC-specific cre expres-
sion utilizing Ncr1 regulatory elements (Eckelhart et al., 2011;
Narni-Mancinelli et al., 2011) have limitations. In these models,
cre expression initiates with normal Ncr1 gene expression in
immature BM stage I NK cells (Walzer et al., 2007). Hence,
loxP-directed excision events occur early in NK cell develop-
ment, precluding the study of developmentally critical genes in
mature NK cells. To overcome this barrier, we developed a
type-1-ILC-specific, tamoxifen-inducible cre mouse (Figure 1A)
generated by genetic targeting of a tamoxifen-responsive
iCreERT2 cassette into the Ncr1 locus. This cassette is linked
to NKp46 C-terminal translation via a P2A ribosomal skip site.
This Ncr1-iCreERT2 model was crossed to a reporter allele con-
sisting of a lox-stop-lox (LSL)-flanked YFP cassette genetically
targeted to the Rosa26 locus in order to track cre nuclear activity
(Srinivas et al., 2001). To test the timing of cre expression in this
model, mice underwent oral gavage with 3 mg tamoxifen for 3
consecutive days (Heger et al., 2014; Herold et al., 2014), and
3 days later, YFP expression was analyzed in various tissues
(Figure 1B). YFP expression was observed in NKp46+ cells of
the blood, spleen, and liver (R90% YFP+) as well as BM and
lymph node (LN) (R80% YFP+). YFP expression was restricted
to NKp46+ cells and not expressed by other hematopoietic line-
ages, including T cells (Figure 1B; data not shown). Similar to
other iCreERT2 models (Kristianto et al., 2017; Maurel et al.,
2019), mature (8- to 12-week-old) Ncr1-iCreERT2 mice had small
background levels of cre nuclear localization (5%–10%) in
NKp46+ cells in the absence of tamoxifen that increased slowly
over time (Figures 1B and S1). Therefore, in this report, experi-
ments were performed in 8- to 12-week-old mice unless other-
wise noted.
This model is also useful to assess cellular dynamics within the
NKp46+ ILC compartment. NK cells and tissue-resident ILC1s
were compared in a 3-day tamoxifen ‘‘pulse’’ YFP ‘‘chase’’
experiment. Here, we treated Ncr1-iCreERT2 3 Rosa26YFPLSL
micewith tamoxifen and then assessed splenic and liver NK cells
aswell as liver ILC1s for YFP positivity over the next 5weeks. The
proportion of YFP+ liver ILC1s remained high (R90%), consis-
tent with replenishment from NKp46+ tissue-resident popula-
tions and/or less cellular attrition. In contrast, splenic and liver
NK cells displayed considerable turnover, and YFP positivity re-
turned to near-baseline levels by the end of the 5-week period
(Figure 1C). Thus, Ncr1-iCreERT2 x Rosa26YFPLSL mice ex-
hibited robust and specific cre activity in NKp46+ ILCs after
tamoxifen administration, which was tracked in subsequent ex-
periments using YFP. For the remainder of the study, experi-
ments were performed at three time points relative to tamoxifen
administration: Tam-3d, Tam-6d, and Tam-9d (Figure 1D).
Tamoxifen Rapidly Eliminates Eomes in NKp46+ Cells of
Ncr1-iCreERT2 3 Eomesfl/fl Mice
We next crossed Ncr1-iCreERT2 3 Rosa26YFPLSL mice to mice
with floxed Eomes alleles (Zhu et al., 2010). Eomes allele excision
was confirmed in splenocytes of Ncr1-iCreERT2 KI/WT 3
Rosa26YFPLSL 3 Eomesfl/fl (henceforth ILC-EomesD/D) mice
(C) Ncr1-iCreERT23 Rosa26YFPLSL mice were treated with three consecutive daily doses of tamoxifen. Summary data showmean ± SEM. YFP positivity among
splenic NK cells, liver NK cells (CD49a DX5+) and liver ILC1 cells (CD49a+ DX5) weekly for 5 weeks thereafter. n = 2 mice per group, one experiment.
(D) Schematic of tamoxifen regimens.
(E) PCR was performed for the presence of Eomes floxed (fl; 730 bp) or WT (620 bp) alleles on heterozygous Eomesfl/WT control genomic DNA (lanes 1 and 2) and
YFP+ splenic NK cells (NK1.1+ CD3, lane 3) or T cells (CD3+, lane 4) sorted from ILC-EomesD/Dmice treatedwith the Tam-3d regimen. Empty lanes were cropped
as shown by the border.
(F) Tam-6d-treated Eomes WT and ILC-EomesD/D mouse tissues were analyzed for Eomes expression. Summary data show mean ± SEM percent Eomes
positivity in YFP+NKp46+ cells. Representative flow histograms show Eomes protein in EomesWT (shaded blue line) and ILC-EomesD/DNK cells (empty blue line),
and NK1.1 CD3 lymphocytes (background, shaded gray) in the spleen and BM. n = 5 Eomes WT mice, 9 ILC-EomesD/D mice, two independent experiments.
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Figure 2. Induced Eomes Deletion Results in a Significant Decrease in Global NK Cell Numbers, with
a Particularly Profound Loss of Stage III NK Cells
(A) Mean ± SEM. YFP+ NKp46+ cell percentage of lymphocytes and number in the blood (Bl; per mL), spleen (Sp), BM (per femur), LN (per inguinal LN), or liver (Liv)
of ILC-EomesD/D versus WT mice following the Tam-6d regimen.
(legend continued on next page)
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after the Tam-3d regimen, as PCR analysis of the Eomes locus
revealed excision in flow-sorted YFP+ NK cells but not YFP
T cells (Figure 1E). This was verified at the protein level after
the Tam-6d regimen using flow cytometry in ILC-EomesD/D
compared to control NK cells (Figure 1F). Thus, tamoxifen-
induced cre efficiently translocated to the nucleus and excised
Eomes in mature NK cells within 2 days.
Induced Eomes Deletion Results in a Rapid Loss of NK
Cells, Most Prominently Stage III
To assess the impact of induced Eomes deletion on the NK cell
compartment, we treated ILC-EomesD/D and control mice with
the Tam-6d regimen and then assessed NK cell numbers and
maturation. We observed a significant decrease in global YFP+
NK cell numbers in ILC-EomesD/D compared to wild-type (WT)
control mice in all tissues examined (blood, spleen, BM, LN,
and liver; Figure 2A). Notably, induced Eomes deletion had a
particularly profound effect on less mature stage II
(CD27+CD11b) and stage III (CD27+CD11b+) NK cells. Stage
III NK cells, in particular, were significantly decreased in number
and percentage in all tissues analyzed (Figure 2B). While stage IV
(CD27CD11b+) NK cell numbers were reduced in the blood,
BM, and LN in ILC-EomesD/D mice, their relative proportion
increased in all tissues except the liver, where it was unchanged.
As expected, Eomes-dependent NK cells were decreased in
both the proportion of YFP+ NKp46+ cells and absolute number
in the liver, while the proportion of Eomes-independent ILC1s
increased, but numbers remained unchanged (Figure 2C) (Sojka
et al., 2014). Despite evidence that Eomes and T-bet negatively
cross-regulate one another (Daussy et al., 2014), we did not
observe increased T-bet protein levels in ILC-EomesD/D NK cells
(Figure 2D). Thus, induced Eomes deletion negatively affects NK
cell numbers and homeostasis, particularly those of the stage III
subset.
Loss of Stage III NK Cells in ILC-EomesD/DMice Results
from Apoptosis and Altered Cell-Cycling Dynamics
Wehypothesized that the decrease in NK cell numbers observed
following Eomes deletion could be the result of enhanced
apoptosis or altered cell cycling. This was tested at an earlier
time point after tamoxifen gavage (Tam-3d), when cells undergo-
ing apoptosis or attempting toproliferatemaystill bequantifiable.
At this time point, >70% of splenic ILC-EomesD/D and control NK
cells were YFP+, Eomes protein was nearly absent, and reduc-
tions in NK cells had started but were more modest compared
to the Tam-6d time point (Figures 3A and 3B). A significantly
greater fraction of apoptotic (Annexin V+) stage III NK cells were
present in the spleen and BM of ILC-EomesD/D compared to
WT mice (Figure 3C). This was associated with a significant in-
crease in caspase activation in splenic stage III NK cells of ILC-
EomesD/D compared to control mice (Figure 3D). To further un-
derstand this apoptosis phenotype, we performed unbiased
RNA sequencing (RNA-seq) of flow-sorted stage II, III, and IV
ILC-EomesD/D and WT splenic NK cells. Gene set enrichment
analysis (GSEA) of the RNA-seq data revealed significant enrich-
ment of the Hallmark Apoptosis Pathway in ILC-EomesD/D,
compared to WT, stage II NK cells (Figure 3E). This enrichment
was not observed in stage III or IV NK cell comparisons (Fig-
ureS2). Thesedata are consistentwith the observed loss of stage
III NK cells, as they suggest that induced Eomes deletion acti-
vates apoptotic machinery in stage II NK cells that die at stage III.
ILC-EomesD/DandWTNKcellswere also co-stained for Ki67 (a
marker of proliferation) and DNA content to assess cell-cycle dy-
namics (Figures 3F, 3G, and S3A). The cell-cycle distribution of
bulk, stage II, and stage IV NK cells was identical between WT
and ILC-EomesD/Dmice in the spleen andBM (Figure S3B). How-
ever, a significantly greater percentage of stage III NK cells were
inG1 in ILC-EomesD/D compared toWTmice (Figure 3F). No cells
progressed to S/G2/M, however, even when analyzed an addi-
tional day after the Tam-3d regimen (Figure 3G). This suggests
that induced Eomes deletion promotes a G0 to G1 transition in
stage III NK cells, yet the cell cycle is unable to progress beyond
that point, possibly due to cell-cycle-arrest-related apoptosis.
Eomes-deleted NK cells are capable of cell division, however,
as demonstrated via transfer experiments into a homeostatic
proliferation environment (Figure S4). Here, both ILC-EomesD/D
andEomesWTYFP+splenicNKcells showed robust andcompa-
rable proliferation 14dayspost-transfer intoRag2/gc/ recip-
ientmice (Figure S4B).While restrictions on our flowpanel did not
allow for stage-specific analyses, given the deleterious effect of
Eomes on stage III NK cell numbers, we hypothesize that the
proliferated ILC-EomesD/D NK cells were largely stage II and IV.
Short-term proliferation of ILC-EomesD/D and WT YFP+ NK cells
after 4 days in vivo was also similar but significantly reduced
compared to cre-negative NK cells, suggesting that induction
of cre concurrent with a strong proliferation signal may alter
normal cellular proliferation (Figure S4A) (Loonstra et al., 2001).
Collectively, these findings suggest that Eomes loss promotes
stage III apoptosis either by directly activating apoptotic genes
in precursor stage II NK cells or as a result of cell-cycle arrest.
IL-15 Signaling Is Altered in Stage II and III NK Cells as a
Result of Induced Eomes Deletion but Does Not Account
for Stage III NK Cell Loss
Interleukin-15 (IL-15) is the major cytokine involved in NK cell
development, survival, and proliferation. Three major pathways
are activated downstream of the IL-15 receptor (IL-15R): JAK/
STAT (JAK1/3 and STAT3/5), mitogen-activated protein kinase
(B) Summary data showmean ± SEM. YFP+ NK1.1+ cell stage-specific percentages and numbers in ILC-EomesD/D or EomesWTmice in the five different tissues.
ILC1s are included in liver gating. Representative flow cytometry data are shown for the spleen.
(C) Summary data showmean ± SEM. YFP+ NK cell (CD49aDX5+) versus ILC1 (CD49a+ DX5) percentage and numbers in the liver. n = 9 ILC-EomesD/D mice, 5
Eomes WT mice, two independent experiments.
(D) Summary data showmean ± SEM. T-bet MFI in YFP+ ILC-EomesD/D andWT NKp46+ cells across the type 1 ILC compartment, normalized to the mean T-bet
MFI of ILC-EomesD/D NKp46+ cells in each tissue. n = 9 ILC-EomesD/Dmice, 5 EomesWTmice, two independent experiments. Data were compared using false-
discovery-rate-corrected t tests.
*p < 0.05, **p < 0.01, ***p < 0.001.
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(MAPK), and phosphatidylinositol 3-kinase (PI3K) (Mishra et al.,
2014). STAT5, in particular, is known to be critical for NK cell sur-
vival, since it promotes the transcription of anti-apoptotic mole-
cules like Bcl-2 andMcl-1 (Huntington et al., 2007; Ranson et al.,
2003). Since Eomes is known to regulate the b chain of the IL-
15R (CD122) (Intlekofer et al., 2005), we hypothesized that
induced Eomes deletion resulted in decreased expression of
the intermediate-affinity (b/g) IL-15R and thus decreased IL-15
signaling and STAT5 phosphorylation in vivo, leading to stage
III NK cell apoptosis. Indeed, a significant decrease in CD122
expression on both stage II/III and stage IV Tam-3d-treated
ILC-EomesD/D compared to WT NK cells was observed (Fig-
ure 4A). We used phospho-flow cytometry to interrogate activa-
tion of downstream signaling pathways in response to low-dose
(10 ng/mL) and high-dose (100 ng/mL) IL-15 in NK cells fromWT
and ILC-EomesD/D mice treated with the Tam-3d regimen (Fig-
ure 4B). Unexpectedly, we observed no defect in pSTAT5 activa-
tion at either IL-15 concentration tested and, accordingly, no
Figure 3. Induced Eomes Deletion Results in Increased Stage III NK Cell Apoptosis and Altered Cell-Cycling Dynamics
ILC-EomesD/D and Eomes WT mice were treated with the Tam-3d regimen, and then apoptosis and cell cycling dynamics were assessed.
(A) YFP expression, percentage, and number of splenic ILC-EomesD/D and Eomes WT NK cells. n = 5–6 mice per group, two independent experiments.
(B) Mean ± SEM percentage of Eomes+ splenic NK cells. Representative flow histogram shows Eomes protein in splenic Eomes WT (shaded blue line) and ILC-
EomesD/D NK cells (empty blue line), and NK1.1- CD3- lymphocytes (background, shaded gray). n = 8 ILC-EomesD/Dmice, 4 Eomes WT mice, two independent
experiments.
(C) Mean ± SEM. Annexin V+ ILC-EomesD/D or Eomes WT NK cells by stage in the BM and spleen. n = 12–17 mice per group, four to seven independent ex-
periments.
(D) Mean ± SEM percent of ILC-EomesD/D or Eomes WT splenic stage II or III NK cells with activated poly-caspase expression. n = 5–6 mice per group, two
independent experiments.
(E) GSEA of RNA-seq data from ILC-EomesD/D and EomesWT stage II NK cells. An enrichment plot for the hallmark apoptosis pathway is shown to the left, with all
significantly enriched or downregulated pathways shown to the right.
(F) Mean ±SEMproportion of G0, G1, and S/G2/M stage III EomesWT and ILC-EomesD/DNK cells in the spleen and BM,with representative flow plots shown. n =
9–12 mice per group, three or four independent experiments.
(G) Mean ± SEM proportion of G0, G1, and S/G2/M stage III ILC-EomesD/D and EomesWT NK cells in the spleen and BM one day after the Tam-3d regimen. n = 6
mice per group, two independent experiments. Data were compared using t tests with false discovery rate correction where appropriate.
*p < 0.05, **p < 0.01, ***p < 0.001.
Figure 4. Induced Eomes Deletion Results in Modest Differences in IL-15 Signaling
(A) Mean ± SEM. CD122 MFI on stage II/III (CD27+) versus stage IV (CD27CD11b+) splenic NK cells from Eomes WT and ILC-EomesD/D mice treated with the
Tam-3d regimen. Representative flow histograms also shown. n = 6 mice per group, two independent experiments.
(B) Mean ± SEM pSTAT5, pERK, and pAkt MFI fold change over baseline (unstimulated) in splenic NK cells from EomesWT and ILC-EomesD/Dmice treated with
the Tam-3d regimen. Cells were stimulated with 10 or 100 ng/mL IL-15 for 15min (pSTAT5) or 1 h (pERK, pAkt). n = 7–10mice per group, three or four independent
experiments. Data were compared using t tests.
*p < 0.05, **p < 0.01, ***p < 0.001.
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difference in Bcl-2 protein expression between ILC-EomesD/D
and WT NK cells (Figure S5A). In contrast, pERK and pAkt
median fluorescence intensity (MFI) was decreased in ILC-
EomesD/D compared to WT stage II/III NK cells in response to
low-dose, but not high-dose, IL-15. This is consistent with higher
levels of IL-15 being required to activate these pathways,
compared to STAT5, in murine NK cells (Marc¸ais et al., 2014).
While they are not considered to be the principal regulators of
NK cell apoptosis, the PI3K/Akt/mTOR and MAPK pathways
have been shown to play important roles in promoting NK cell
survival (Huntington et al., 2007). However, stage III NK cells
were not rescued in mice that received exogenous IL-15
concomitantly with tamoxifen (Figures S5B–S5D). Thus, the
negative effect of Eomes deletion on stage III NK cell survival
is likely not the result of impaired IL-15 signaling.
Induced Eomes Deletion Impairs NK Cell Maturation
In Vivo
The PI3K and MAPK pathways are involved in other aspects of
NK cell homeostasis, including maturation (Tassi et al., 2007).
We hypothesized that the stage III NK cell defect might also be
due to impaired maturation from precursor stage II cells. To
test this hypothesis, we treated ILC-EomesD/D and WT mice
with the Tam-3d regimen then sorted YFP+ CD27+ (stage II/III)
or YFP+ CD27 CD11b+ (stage IV) NK cells, transferred them
into congenic recipients, and allowed them tomature for 2weeks
in vivo (Figure 5A) (Sullivan et al., 2015). Stage IV NK cells from
both ILC-EomesD/D and WT control mice were stable and re-
mained stage IV after 2 weeks (Figure 5B), contrary to previous
results utilizing ex vivo TAT-cre-induced Eomes deletion (Gordon
et al., 2012). However, themajority of ILC-EomesD/DNKcells that
were stage II/III at the time of transfer were stage II after 2 weeks
in vivo, with only a small number of stage IV NK cells developing.
This was in contrast to WT cells that showed expected in vivo
maturation (Figures 5B and 5C). To account for any bias intro-
duced by sorting on YFP+ cells, this experiment was repeated
by sorting stage II/III or stage IV cell trace violet (CTV)-labeled
NK cells from ILC-EomesD/D or CD45.1 WT mice prior to tamox-
ifen, and co-transferring cells of the same stage into CD45.2 re-
cipients. The recipient mice were then treated with 3 days of
tamoxifen, and in vivo maturation was assessed 2 weeks later
with similar results (Figure S6). These in vivo maturation experi-
ments indicate that Eomes is required for normal stage II to III
NK cell maturation. Thus, the particularly profound defect in
stage III NK cells following Eomes deletion also arises from a
stage II to III maturation block.
Figure 5. Eomes Is Required for Normal NK Cell Maturation
(A) ILC-EomesD/D and Eomes WT mice were treated with the Tam-3d regimen. Splenic NK cells were sorted to YFP+CD27+ (stage II/III) or YFP+CD27CD11b+
(stage IV) and transferred into CD45.2 WT recipients. 2 weeks later, YFP+ cell maturation was assessed.
(B) Stage distribution of ILC-EomesD/D or Eomes WT sorted stage II/III or IV NK cells before (light blue) or 2 weeks after transfer (dark blue).
(C) Representative flow cytometry data showingmaturation of stage II/III ILC-EomesD/D or EomesWTNK cells after 2 weeks in vivo. NR 3 pooledmice per group,
three independent experiments. Data were compared using t tests.
*p < 0.05, **p < 0.01, ***p < 0.001.
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Eomes Deletion Impairs NK Cell Cytotoxicity, but Not
Cytokine Production
ILC-EomesD/D mice were next used to assess the impact of
Eomes deletion on mature NK cell function. To assess ex vivo
cytotoxic responses, we treated ILC-EomesD/D and WT mice
with the Tam-3d regimen, and on the 2nd day of tamoxifen also
administered poly(I:C), a synthetic Toll-like receptor 3 (TLR3)
agonist that activates NK cells (Fehniger et al., 2007). 24 h later,
splenocytes were harvested, and enriched NK cells were used
as effectors in flow-based killing assays against MHC-class I-
deficient RMA-S leukemia targets. We observed a significant
decrease in RMA-S killing by ILC-EomesD/D NK cells at both
effector-to-target ratios examined (Figure 6A). NK cells were
equally enriched in the two groups (Figure 6B), demonstrating
that the killing defect was not due to different numbers of ILC-
EomesD/D versus control NK cells, but rather was cell-intrinsic.
NK cell killing of target cells involves the targeted release of cyto-
toxic-protein-containing granules. Granzyme B protein levels
were not affected by induced Eomes deletion (Figure 6C),
consistent with prior reports showing robust granzyme B protein
levels in Eomes-deficient ILCs (Gordon et al., 2012). However,
RNA-seq analysis revealed a R2-fold decrease in perforin
mRNA in stage II and III ILC-EomesD/D relative to WT NK cells
(Figure S7A), consistent with prior reports of NK cell perforin
regulation by Eomes (Intlekofer et al., 2005). Indeed, we per-
formed Eomes chromatin immunoprecipitation sequencing
(ChIP-seq) on primary, IL-15-expanded murine NK cells and
confirmed the Prf1 transcription start site to be a direct target
of Eomes (Table S1). In addition, since inducible Eomes deletion
might impact the NK cell granular exocytosis pathway more
globally (Galandrini et al., 2013), we performed GSEA of our
RNA-seq data for the Kyoto Encyclopedia of Genes and Ge-
nomes (KEGG) NK-cell-mediated cytotoxicity pathway and
observed significant downregulation of this pathway in ILC-
EomesD/D compared to WT NK cells of all stages (Figure S7B).
Thus, induced Eomes deletion appears to affect several compo-
nents of the NK cell cytotoxic program, including perforin.
To complement cytotoxicity assessments, we examined
in vitro NK cell cytokine and degranulation (surface CD107a) re-
sponses after stimulation. A time course of ILC-EomesD/D versus
WT NK cell function following the Tam-3d, Tam-6d, or Tam-9d
regimens was utilized (Figures 6D and 6E). At each time point,
we observed no differences in ILC-EomesD/D versus WT NK
cell degranulation or IFN-g production in response to cytokine
(IL-12/15) stimulation, YAC-1 lymphoma, or activating receptor
NK1.1 ligation (Figure 6D). We also investigated stage-specific
ILC-EomesD/D versus WT NK cell function, and similarly, there
were few substantial differences. The most consistent was a
modest deficit in ILC-EomesD/D stage II NK cell functional re-
sponses to anti-NK1.1 ligation (Figure 6E). Thus, in vitro NK
cell cytokine and degranulation responses were largely pre-
served upon induced Eomes deletion, despite reduced ex vivo
cytotoxicity.
Induced Eomes Deletion Impairs Rejection of MHC-
Class-I-Deficient Splenocytes In Vivo
To investigate the importance of induced Eomes deletion on NK
cell function in vivo, we assessed the ability of NK cells to reject
MHC-class I-deficient targets (Bix et al., 1991). ILC-EomesD/D
andWTmice were treated with the Tam-3d regimen and injected
intravenously (i.v.) on day 3 with a 50:50 mix of WT and b2 m/
(MHC-class-I-deficient) splenocytes. 18–20 h later, mice were
sacrificed and the WT:b2 m/ ratio of transferred cells in the
spleen assessed (Figure 7). b2 m/ cells were efficiently re-
jected in WT mice, but no rejection occurred in ILC-EomesD/D
mice (Figures 7A–7C). Indeed, the WT:b2 m/ ratio of trans-
ferred cells in the spleen after 18–20 h was the same for ILC-
EomesD/D mice as it was for negative control mice that had
been NK cell depleted. Alterations in the NK cell Ly49 repertoire
could underlie this finding, and prior publications have demon-
strated that Eomes is required for the generation of a diverse
Ly49 repertoire, but not its maintenance (Gordon et al., 2012).
However, there were no substantial differences in Ly49 receptor
expression between ILC-EomesD/D andWT NK cells (Figure 7D),
suggesting that Ly49 alterations were unlikely to account for the
impaired in vivo rejection phenotype. Thus, the impaired ex vivo
cytotoxicity of ILC-EomesD/D NK cells was manifest in vivo, as
the cells showed no ability to reject MHC-class-I-deficient
targets.
DISCUSSION
The role of Eomes in mature NK cell homeostasis and function
has been incompletely understood, in large part due to a lack
of inducible, conditional genetic models. Constitutive Ncr1-cre
and Vav-cre models have conclusively demonstrated that
DX5+ NK cells fail to develop in the absence of Eomes (Gordon
et al., 2012; Pikovskaya et al., 2016).While some studies attemp-
ted to investigate the functional and phenotypic properties of
cells that did develop in these models, particularly in the liver,
these results are challenging to interpret in light of our current un-
derstanding that these were ILC1s and not Eomes-deficient NK
Figure 6. Induced Eomes Deletion Does Not Significantly Alter NK Cell Functional Responses but Impairs Ex Vivo Cytotoxicity
(A and B) ILC-EomesD/D or Eomes WT mice were treated with the Tam-3d regimen. On day 2 of tamoxifen, mice were also administered 300 mg poly(I:C)
intraperitoneally (i.p.) 24 h later, NK cells were enriched from splenocytes pooled from 2-3 mice per group and used in a flow-based killing assay against RMA-S
targets. (A) Percent specific killing of RMA-S cells at the indicated effector/target ratios and (B) mean ± SEM. NK cell percentage of CD45+ cells from splenocytes
used in the killing assay. n = 3 sets of pooled mice per group, three independent experiments.
(C) Mean ±SEMgranzymeB percent positive andMFI of NK cells immediately before (in the blood) and 24 h after (in the spleen) poly(I:C). n = 7–11mice per group,
two or three independent experiments.
(D and E) Splenocytes from ILC-EomesD/D or Eomes WT mice treated with the Tam-3d, Tam-6d, or Tam-9d regimens were stimulated with plate-bound anti-
NK1.1, IL-12 (10 ng/mL) + IL-15 (10 ng/mL) or YAC-1 lymphoma targets (10:1 effector:target [E:T]) in a 6-h functional assay. Summary data show (D) overall mean
± SEM percent IFN-g or CD107a positive NK cells and (E) IFN-g and CD107a positivity by stage in response to the different stimuli. n = 8–9 mice per group, three
independent experiments. Data were compared using false-discovery-rate-corrected t tests.
*p < 0.05, **p < 0.01, ***p < 0.001.
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cells. Since constitutive Ncr1-cre and Vav-cre models delete
genes early in NK cell development (stage I or earlier), they pre-
clude the study of genes required for normal NK cell ontogeny
(like Eomes). In addition, global inducible models are compli-
cated by cell-extrinsic effects and the requirement for adoptive
transfer experiments (Madera et al., 2018). To overcome these
limitations, we developed a highly penetrant, tamoxifen-induc-
ible type-1-ILC-specific cre mouse. A transgenic inducible
model that expressed cre in a small minority of NKp46+ cells
was previously reported but lacked highly penetrant type 1
ILC-specific gene targeting (Nabekura and Lanier, 2016). The
Ncr1-iCreERT2 reported here results in near-complete Eomes
protein loss throughout the NK cell compartment in 2 days and
permitted the demonstration of a persistent requirement for
Eomes in mature NK cell homeostasis and function. Like most
cre-loxP systems, our Ncr1-iCreERT2 model has limitations that
must be considered during experimental design, including small
background levels of cre expression in older mice and potentially
altered proliferation kinetics. These limitations reinforce the
importance of having a reporter for cre activity in experimental
mice.
Eomes deletion negatively affected NK cell homeostasis, with
a particularly profound effect on stage III NK cells. We deter-
mined that the stage III deficit arose from several mechanisms,
including increased apoptosis (likely caspase dependent),
altered cell cycling, and impaired maturation from stage II NK
cells. IL-15-induced activation of PI3K/Akt/mTOR and MAPK
was impaired in response to low-dose IL-15 in ILC-EomesD/D
NK cells, yet exogenous IL-15 failed to rescue stage III NK cells
in vivo. Thus, Eomes appears to regulate NK cell survival via
mechanisms that are not rescued by exogenous IL-15. Indeed,
we observed enrichment of apoptosis-related genes specifically
in ILC-EomesD/D compared to WT stage II NK cells, which likely
undergo cell death as they transition to stage III. These data
reveal a role for Eomes in regulating hematopoietic cell
apoptosis, a greater understanding of which could potentially
lead to novel ways of supporting NK cells in the setting of adop-
tive transfer. The deficit in PI3K and MAPK activation by IL-15 at
physiologic cytokine levels could, however, contribute to the
maturation defect observed in stage II ILC-EomesD/D NK cells
(Tassi et al., 2007). Importantly, and in contrast to prior models
that induced Eomes deletion ex vivo in mature NK cells (Gordon
et al., 2012), we demonstrate that mature (stage IV) NK cells are
largely Eomes independent and do not revert to an immature
state if Eomes is lost. In addition, althoughwe saw no overall def-
icits in NK cell homeostatic proliferation upon induced Eomes
deletion, stage-specific analyses as well as investigations of
activation or inflammation-driven proliferation were not per-
formed and will be important to fully appreciate the impact of
Eomes deletion on NK cell proliferation. For the last decade,
NK cell maturation has largely been classified based on CD27
and CD11b expression (Chiossone et al., 2009). Our findings
Figure 7. Inducible EomesDeletion Impairs In VivoNKCell Rejection
of b2 m/ Splenocytes
(A–C) Eomes WT and ILC-EomesD/D mice were treated with the Tam-3d
regimen. On day 3, mice received tamoxifen as well as 23 106WT and 23 106
b2 m/ splenocytes via tail vein injection. Transferred splenocytes were
CFSE+ and differentially labeled with CTV. 18–20 h later, mice were sacrificed,
and the WT versus b2 m/ content of CFSE+ splenocyte events was as-
sessed. As a control for NK-independent killing, some mice received 200 mg
anti-NK1.1 antibody i.p. 2 days before splenocyte transfer. (A) b2 m/ versus
WT composition of transferred (CFSE+) splenocytes 18–20 h post-transfer with
representative flow in (B). (C) Mean ± SEM percent rejection by ILC-EomesD/D
versus WT mice. Percent rejection = (1  [(ratio WT:b2 m /)experimental/(ratio
WT:b2 m/)NK depleted]) 3 100. n = 10 Eomes WT mice, 10 ILC-Eomes
D/D KO
mice, 6 NK-depleted mice, two independent experiments.
(D) Ly49 repertoire of Eomes WT and ILC-EomesD/D YFP+ NK cells following
the Tam-3d regimen. n = 8–11 mice, three or four independent experiments.
Data were compared using t tests with false discovery rate correction where
appropriate.
*p < 0.05, **p < 0.01, ***p < 0.001.
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suggest that an alternate way of characterizing NK cell matura-
tion is based on Eomes dependence. As such, stage II/III NK
cells are Eomes dependent, while stage IV NK cells are predom-
inantly Eomes independent. Terminally mature NK cells downre-
gulate Eomes and upregulate T-bet, and so we hypothesize that
stage IV NK cell homeostasis is T-bet dependent. Additional
studies utilizing the inducible cre model with both T-bet and
Eomes floxed alleles will clarify these T-box transcription factor
requirements.
Functionally, we observed that induced Eomes deletion
impaired NK cell killing, as evidenced by both in vivo rejection
of MHC-class-I-deficient splenocytes and ex vivo killing of tumor
target cells. While the decreased NK cell number arising from
induced Eomes deletion could be a contributing factor, the killing
defect in vivowas disproportionate to the NK cell deficit, and the
ex vivo killing assay was performed with equal NK cell numbers.
Thus, Eomes deletion impairs NK cell killing in vivo and ex vivo via
NK-cell-intrinsic mechanisms. NK cells kill via exocytosis of
cytotoxic-protein-containing granules and via the ligation of
death receptors on target cells. Ongoing Eomes-regulated tran-
scription is not required for short-term granzyme B protein
expression, as we observed no reduction in granzyme B protein
levels in ILC-EomesD/D compared to WT NK cells. In contrast,
RNA-seq revealed a significant reduction in perforin mRNA in
ILC-EomesD/D stage II and III NK cells compared to WT, and
Eomes ChIP-seq confirmed Prf1 to be an NK cell target of
Eomes. While we were unable to quantify perforin protein due
to technical limitations of available flow-based antibodies, de-
creases in perforin protein are likely to have occurred given the
perforin sensitivity of RMA-S cells (Wallin et al., 2003) . However,
perforin mRNA was unchanged by induced Eomes deletion in
stage IV NK cells, and since these cells are major NK cytotoxic
mediators, this suggested that other components of the NK
cell cytotoxic machinery may have been altered by induced
Eomes deletion. Indeed, we observed downregulation of the
KEGG NK-cell-mediated cytotoxicity pathway in ILC-EomesD/D
NK cells of all stages, demonstrating a broader role for Eomes
in regulating NK cell cytotoxicity. It is also possible that alter-
ations in death receptor ligand expression contributed to the
killing defects observed. Tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL), in particular, is expressed
on tissue-resident, Eomes-negative ILC1s, so it is possible that
it is upregulated upon Eomes deletion. However, RMA-S cells
are relatively TRAIL and FasL resistant in short-term killing as-
says (Screpanti et al., 2001; Wallin et al., 2003). Thus, while it
will be important to investigate death receptor ligand expression
and function on ILC-EomesD/D NK cells in the future, they likely
did not contribute substantially to our cytotoxicity phenotype.
Unlike the cytotoxicity results, short-term NK cell degranula-
tion and IFN-g production were largely unaltered by induced
Eomes deletion. It has been suggested that Eomes may be
important for sustained NK cell functional responses and that
Eomes downregulation, for example in cells infiltrating a tumor,
might be a sign of NK cell exhaustion (Gill et al., 2012). As
such, it will be informative to perform studies of sustained NK
cell function (such as infection with murine cytomegalovirus
[MCMV] or tumors) using our inducible cre system to assess
the role of Eomes in these types of NK cell responses. Intrigu-
ingly, our ChIP-seq data, performed on IL-15-expanded NK
cells, revealed a weak binding peak near the granzyme B pro-
moter (Table S1). We speculate that in settings of sustained acti-
vation, Eomes may play a role in regulating the expression of this
cytotoxic protein as well and that this may be a mechanism
through which Eomes loss contributes to NK cell exhaustion. A
greater understanding of how Eomes deletion affects the entire
NK-cell-activating (e.g., NKG2D and NKp30) and inhibitory
(e.g., NKG2A) repertoire will also be important to fully understand
virus and tumor model findings.
This conditional, inducible cremodel hasmany potential appli-
cations beyond the study of developmentally critical genes,
which will make it important for addressing other outstanding
questions in the type 1 ILC field. For example, it could be used
to study NK cell populations that arise only after specific physio-
logic triggers, such as MCMV-specific innate memory or cyto-
kine-inducedmemory-likeNKcells. In addition, sincewedemon-
strated that ILC1s regenerate at amuchslower rate thanNKcells,
or from NKp46+ precursors, this model may be useful to selec-
tively ablate genes within ILC1s, thereby permitting studies of
the in vivo functions of these distinct but related cell types.
Thus, this study provides a critical tool for the field to address
newquestions and avenues of investigation in type 1 ILC biology.
Limitations
Submission of this manuscript occurred during the SARS-CoV-2
pandemic, limiting our ability to perform experiments to address
all issues raised during peer review. Some experiments, while of
great interest, were beyond the feasible scope of the manuscript
in light of restrictions imposed to contain the pandemic. These
issues will be addressed in future studies, including (1) whether
death receptor ligands (TRAIL and FasL) are differentially ex-
pressed on ILC-EomesD/D versus control NK cells and whether
they contribute significantly to ILC-EomesD/D NK cell cytotox-
icity; (2) whether induced Eomes deletion alters sustained NK
cell function, as determined by an in vivo virus or tumormodel; (3)
if the expression of other activating and inhibitory receptors (e.g.,
NKG2D, NKp30, andNKG2A) differs between ILC-EomesD/D and
control NK cells; (4) evaluation of perforin protein in addition to
decreased mRNA in stage II and III ILC-EomesD/D NK cells;
and (5) a comprehensive assessment of the impact of Eomes
deletion on NK cell proliferation.
In summary, we developed a type-1-ILC-specific inducible cre
mouse to identify a stage-specific requirement for Eomes in
regulating NK cell homeostasis and cytotoxicity. In addition to
elucidating the role of Eomes in mature NK cell biology, this
study highlights the importance of complementing studies of
constitutive cre with inducible models in order to elucidate the
biological roles of genes at all stages of cellular development.
As such, we anticipate that theNcr1-iCreERT2 model will provide
important insights into the nascent field of type 1 ILC biology.
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Todd A.
Fehniger (tfehnige@wustl.edu).
Materials Availability
TheNcr1-iCreERT2 mouse generated in this study will be made available to qualified investigators by the Lead Contact, Todd A. Feh-
niger (tfehnige@wustl.edu) upon request.
Data and Code Availability
The accession numbers for the RNaseq and CHIPseq data reported in this paper are GEO:GSE132942 (RNaseq) and
GEO:GSE133048 (ChIPseq).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Ncr1-iCreERT2 mice were developed in the Fehniger lab on the C57BL/6J background. Mice were bred to Rosa26 YFPLSL knock-in
mice (The Jackson Laboratory, stock no. 006148) as well as Eomesfl/fl mice (The Jackson Laboratory, stock no. 017293). For all ex-
periments, ILC-EomesD/D refers to Ncr1-iCreERT2 KI/WT x Rosa26YFPLSL x Eomesfl/fl mice. Ncr1-iCreERT2 KI/WT x Rosa26YFPLSL x
EomesWT/WT mice were used as WT controls in Figures 1E, 2, 3A, 3B, 3D, 3F, 3G, 5, 6A, and 6B, as well as Figures S1 and S3–
S5. In the remaining figures, if these mice were limiting, Ncr1-iCreERT2 WT/WT x Rosa26YFPLSL x Eomesfl/fl mice as well as CD45.1
and CD45.2 C57BL/6J mice (The Jackson Laboratory, nos. 002014 and 000664) were also utilized. CD45.1 C57BL/6J mice were uti-
lized as WT controls in Figure S6 and as cre-negative controls in Figure S4. Rag2/gc/ mice (Taconic, no. 4111) were used as
recipients for in vivo homeostatic proliferation assays (Figure S4). All mice (EomesWT and ILC-EomesD/D) were treated with identical
tamoxifen regimens for all experiments. Mice were orally gavaged with 3mg tamoxifen (Sigma) in corn oil (Sigma) for 2-3 days as
described. Mice were bred and maintained in specific pathogen-free housing, and experiments were conducted in accordance
with the guidelines of and with the approval of the Washington University Animal Studies Committee. Experiments were performed
on 8-12 week old male and female mice.
Cell Lines
RMA-S and YAC-1 cell lines were maintained at 37C in 5% CO2 in RPMI-1640 plus 10% FBS and supplements(10mM HEPES, 1%
NEAA, 1% sodium pyruvate, 1% L-glutamine, 1X penicillin and streptomycin) following ATCC guidelines and kept in continuous cul-
ture for < 2 months.
METHOD DETAILS
Organ isolation and processing
Mice were sacrificed by CO2 asphyxiation and organs harvested immediately. Blood was harvested by cardiac puncture prior to
removal of other organs. Spleens and inguinal nodes were isolated and crushed through a 70 mm filter to generate a single cell sus-
pension. Bone marrow was harvested by flushing femurs with a 23-gauge needle. Whole livers were desiccated with a tissue grinder
then lymphocytes were isolated using a Percoll gradient. All tissues were ammonium-chloride-potassium lysed. Cell counts were
obtained using propium iodide exclusion with a Cellometer counter (Nexcelcom).
Flow cytometry and cell sorting
Surface antibody staining was performed for 15 minutes at 4C. Intracellular staining was performed in permeabilization buffer
following fixation/permeabilization with kits from BD Biosciences (for IFN-g staining) or Invitrogen (for Eomes, Granzyme B, Bcl2,
and Ki67 staining). EomesD/D NK cells (and cre-positive WT cells) were gated on YFP+ events whenever possible. Since Invitrogen
fixation/permeabilization quenches YFP, cells were pre-fixed in 1% PFA for 2 minutes at room temperature prior to fixation/perme-
abilization in order to preserve YFPwhen intracellular proteins were assessed after the Tam-6d regimen (Figures 1E and 2). However,
pre-fixation was unable to preserve YFP after the Tam-3d regimen, so intracellular analyses were performed on bulk NK cells (which
were nearly 80% YFP+, Figure 3A) at this time point. For phosphoflow cytometry assays, splenocytes were stimulated with recom-
binant mouse IL-15 (Peprotech) at 10ng/mL or 100ng/mL for 15 minutes (pSTAT5) or 1 hour (pERK, pAkt). Cells were then fixed with
1% PFA for 10 minutes at room temperature. Next, cells were permeabilized in ice cold methanol for 30 minutes at 4C, then
washed and stained overnight with phosphoflow antibodies. Flow cytometry data were collected on a Gallios flow cytometer
(Beckman Coulter) and analyzed using FlowJo (Treestar) software. Cell sorting was performed on a BD FACS Aria II to greater
than 95% purity.
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Cell cycle and viability assays
Cell cycle was assessed using Ki67 and FxCycle Violet (Invitrogen) staining following Invitrogen Fixation/Permeabilization. For
viability assays, freshly-isolated splenocytes were incubated at 37C for 2-3 hours then assayed for poly-caspase activation (Immu-
nochemistry Technologies) or surface Annexin V (performed in Annexin V buffer, both BD Biosciences).
In vivo maturation experiments
In Figure 5, ILC-EomesD/D and Eomes WT mice were treated with the Tam-3d regimen. Next, NK cells were purified via negative se-
lection (StemCell Technologies, Inc.) from pooled ILC-EomesD/D or Eomes WT spleens and sorted to YFP+ stage II/III (CD27+) or
stage IV (CD27- CD11b+). Cells were injected into separate male CD45.2 WT recipients. 2 weeks later, mice were sacrificed
and the stage distribution of YFP+ splenocytes analyzed via flow cytometry. In Figure S6, NK cells were purified from pooled ILC-
EomesD/D or CD45.1 WT spleens, labeled with CTV (Invitrogen) and sorted to stage II/III (CD27+) or stage IV (CD27- CD11b+) prior
to tamoxifen administration. ILC-EomesD/D and Eomes WT cells of the same stage were pooled and injected into male CD45.2 WT
mice, who then received 3 daily doses of 3mg tamoxifen in corn oil via oral gavage. 2 weeks later, recipient mice were sacrificed and
the stage of CTV+YFP+ (ILC-EomesD/D) and CTV+CD45.1+ (WT) cells analyzed by flow cytometry.
In vivo homeostatic proliferation
ILC-EomesD/D and Eomes WT mice along with Cre- CD45.1 WT controls were treated with the Tam-3d regimen. Splenocytes were
CTV-labeled, then NK cells were purified from pooled splenocytes via negative selection (StemCell Technologies, Inc.) and sorted to
NK1.1+CD3-YFP+ (ILC-EomesD/D and WT) or NK1.1+CD3- (CD45.1WT). Sorted cells were injected in CD45.2 Rag2/gc/ recip-
ients and CTV dilution of YFP+ (ILC-EomesD/D and WT) or CD45.1+ cells (CD45.1 WT) was assessed 4 or 14 days post-transfer via
flow cytometry.
ChIP sequencing
In 3 separate experiments, purified NK cells from pooled CD45.2 Eomes WT splenocytes were expanded in vitro for 4 days with
100ng/mL IL-15. Cells were then harvested and approximately 10 3 106 cells were used per ChIP experiment. Chromatin immuno-
precipiation was performed using the MAGnify Chromatin Immunoprecipitation System (Thermo Fisher) as per manufacturer’s in-
structions with a ChIP-grade anti-Eomes antibody from Abcam (ab23345). Non-immunoprecipitated DNA was used as an input con-
trol. ChIP DNAwas blunt ended, had addition of ‘‘A’’ base to 30 end, and had sequencing adapters ligated to the ends. The fragments
were size selected to 200-600 base pairs, and underwent amplification for 15 cycles with primers incorporating p5 and p7 sequences
and a unique index tag for multiplexing. The resulting libraries were sequenced using the Illumina HiSeq3000 as single reads extend-
ing 50 bases. The raw data was demultiplexed and aligned to the reference genome using Novoalign. MACS was used to call peaks.
For downstream analysis, gene-associated peaks that had greater than 5-fold enrichment over input and were present in all three
replicates (±500 base pairs from each other) were identified (Table S1).
RNA sequencing and Gene Set Enrichment Analysis
In 3 separate experiments, ILC-EomesD/D or CD45.2 Eomes WT mice were treated with the Tam-3d regimen. Next, NK cells were
purified from pooled ILC-EomesD/D or Eomes WT splenocytes and sorted to stage II (CD27+CD11b-), stage III (CD27+CD11b+),
or stage IV (CD27-CD11b+). KO cells were also YFP+. Cells were stored in Trizol at 80C until RNA isolation using the Direct-zol
RNA MicroPrep kit (Zymo Research). NextGen RNA sequencing was performed using an Illumina HiSeq 2500 sequencer. RNA-
Seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b. Gene counts were derived from
the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5. Differential expression analysis was per-
formed to analyze for differences between conditions and the results were filtered for only those genes with Benjamini-Hochberg
false-discovery rate adjusted p values less than or equal to 0.05.
We utilized Gene Set Enrichment Analysis (GSEA) with the Molecular Signatures Database (MSigDB) (Subramanian et al., 2005;
Mootha et al., 2003) developed by the Broad Institute and UC San Diego on the RNA sequencing results of sorted stage II, III,
and IV ILC-EomesD/D and Eomes WT NK cells to identify biological pathways that were enriched or downregulated in ILC-EomesD/D
versus EomesWTNK cells in respective maturation stages. Pathways were considered significantly enriched or downregulated if p <
0.05 and FDR < 0.25.
In vivo b2 m/ rejection
ILC-EomesD/D and WT mice were orally gavaged with 3mg tamoxifen in corn oil for 3 consecutive days. On the third day, mice also
received 4e6 splenocytes that were a 50/50 mix of CD45.2 WT and b2 m/ (a gift fromWayne Yokoyama). Transferred splenocytes
were differentially labeled with CTV for discrimination. In addition, on the first day of tamoxifen administration, some control mice
received 200 mg anti-NK1.1 intraperitoneally (i.p.) to control for non NK-specific killing. 18-20 hours after splenocyte transfer,
mice were sacrificed and the ratio of CTVhi (WT) to CTVlow (b2 m/) splenocytes was assessed. Percent rejection was calculated
as: (1-[(Ratio WT:b2 m/)experimental/(Ratio WT:b2 m
/)NK depleted])*100 (Parikh et al., 2015).
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In vitro cytotoxicity (FLoKA) assays
ILC-EomesD/D andWTmice were administered 3mg tamoxifen in corn oil via oral gavage for 2 consecutive days. On the second day,
mice were also administered 300 mg of poly I:C (Invivogen) i.p. 20-24 hours post-poly I:C, splenocytes were pooled from 2-3mice per
group and NK cells were enriched via negative selection (Stem Cell Technologies). NK-enriched splenocytes were used in killing as-
says against CTV-labeled RMA-S targets at the indicated E:T ratios for 4 hours. Dead cells were identified via 7-AAD staining and
specific killing calculated as: % 7-AAD+effector+target - % 7-AAD+target alone. Mice were cheek bled immediately prior to poly I:C
administration for a baseline NK cell granzyme B readout, and splenic NK cell granzyme Bwas also assessed at the time of the killing
assay.
In vitro functional assays
ILC-EomesD/D and Eomes WT mice were treated with the Tam-3d, Tam-6d, and Tam-9d regimens. At each time point, functional
assays were performed on splenocytes. Splenocytes were either unstimulated (media alone) or stimulated with cytokines (10ng/
mL IL-12 + 10ng/mL IL-15, both Peprotech), YAC-1 lymphoma targets (E:T = 10:1), or plate-bound purified anti-NK1.1 for 6 hours.
Anti-CD107a (LAMP-1) antibody was added at the start of the assay to detect degranulation, and brefeldin A and monensin (BD Bio-
sciences) were added for the final 5 hours. Cells were then surface stained, fixed/permeabilized (BD Biosciences), and intracellularly
stained for IFN-g, follow by flow cytometry analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed using GraphPad Prism 7 software. Tests utilized are indicated in figure legends. * = p < 0.05,
** = p < 0.01, *** = p < 0.001.
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Figure S1. Background cre expression in Ncr1-iCreERT2 mice. Related to Figure 1. Ncr1-iCreERT2 x
Rosa26YFPLSL mice were cheek bled every 2 weeks from 4-18 weeks of age and splenic NK cell YFP
positivity assessed by flow cytometry. N=2-5 mice per group, 1 experiment.
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Figure S2. RNA sequencing reveals stage-specific changes in ILC-EomesΔ/Δvs. Eomes WT splenic NK
cells. Related to Figure 3. (A) Hallmark GSEA of ILC-EomesΔ/Δvs. Eomes WT stage III and IV splenic NK
cells.
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Figure S3. Induced Eomes deletion does not alter bulk, stage II, or stage IV NK cell cycling dynamics.
Related to Figure 3. ILC-EomesΔ/Δ and WT mice were treated with the Tam-3d regimen then cell cycling
dynamics were assessed. (A) Schematic of G0 vs. G1 vs. S/G2/M gating. (B) Mean ± SEM proportion of G0,
G1, and S/G2/M in bulk, stage II, and stage IV ILC-Eomes Δ/Δvs. Eomes WT NK cells from the spleen and
BM. Data were compared using false discovery rate-corrected t-tests.
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Figure S4. Ncr1-iCreERT2 mice have delayed homeostatic proliferation kinetics that are not altered by
induced Eomes deletion. Related to Figure 3. CD45.1 WT (Cre-), ILC-EomesΔ/Δ (Δ/Δ), and Ncr1-
iCreERT2+ Eomes WT (WT) mice were treated with the Tam-3d regimen. On day 3, splenocytes were CTV-
labeled, NK cells purified, and cells were sorted as NK1.1+CD3- (Cre-) or NK1.1+CD3-YFP+ (WT and
Δ/Δ). Sorted cells were transferred into CD45.2 Rag-/-gc
-/- recipients, and homeostatic proliferation (CTV
dilution) was measured 4 or 14 days post-transfer. (A) Mean ± SEM percent proliferated Cre-, WT, or Δ/Δ
NK cells at the Day 4 time point. Representative flow histograms shown to the left. (B) Mean ± SEM
percent proliferated WT or Δ/ΔNK cells at the Day 14 time point. Representative flow data shown to the left
(Cre- shown at Day 4). N = 3-4 mice per group, 1-2 independent experiments. Data were compared using a
one-way ANOVAwith Tukey’s multiple comparisons testing.
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Figure S5. Bcl-2 protein levels are not altered by induced Eomes deletion and high-dose IL-15 does not
rescue ILC-EomesΔ/Δ stage III NK cells. Related to Figure 4. (A) ILC-EomesΔ/Δ and WT mice were
treated with the Tam-3d regimen. Summary data show mean ± SEM splenic NK cell Bcl-2 positivity and
MFI overall and by stage (stage II, III, IV). N = 4-6 mice per group, 1 experiment. Data were compared
using false discovery rate-corrected t-tests. (B-D) ILC-EomesΔ/Δand WT mice were treated with the Tam-3d
regimen and half of the mice received 5mg IL-15 i.p. along with each tamoxifen dose. (B) Mean ± SEM
YFP+ NK cell percent of lymphocytes. (C) Mean ± SEM NK cell percentage by stage. (D) Representative
flow data of NK cell stage distribution. N= 2 mice per group, 1 experiment.
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Figure S6. Eomes is required for normal NK cell maturation in vivo. Related to Figure 5. (A) NK cells
from ILC-EomesΔ/Δ (Δ/Δ) and CD45.1 WT mice were CTV-labeled and sorted to stage II/III or IV. Δ/Δ and
WT cells of the same stage were pooled and co-transferred into CD45.2 WT recipients. Recipient mice
received 3 doses of tamoxifen and maturation of transferred cells was assessed 2 weeks later. (B) Stage
distribution of Δ/Δ or WT sorted stage II/III or IV NK cells pre- (light blue) or 2 weeks post-transfer (dark
blue). (C) Representative flow cytometry data showing maturation of stage II/III Δ/Δ or WT NK cells after 2
weeks in vivo. A modestly increased proportion of stage IV NK cells developed when tamoxifen was
administered post- compared to pre-transfer (Figure 5), likely attributable to experimental variability
combined with the potential bias introduced by sorting on YFP+ NK cells that have likely already initiated
apoptosis. N >3 mice per group, 2-3 independent experiments. Data were compared using t-tests.
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Figure S7. Inducible Eomes deletion results in global decreases in the NK cell cytotoxic program.
Related to Figures 6 & 7. (A) RNA-Seq data of Prf1 mRNA fold change in ILC-EomesΔ/Δ compared to WT
stage II and stage III splenic NK cells. (B) GSEA of the KEGG “Natural Killer Cell Mediated Cytotoxicity”
pathway performed on RNA-Seq data from ILC-EomesΔ/Δ vs. Eomes WT NK cells of different stages
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